⌘K
t
On 14 December 2022, Evgen Pharma plc granted nil cost options over a total of 11,122,199 ordinary shares to certain employees and directors, including PDMRs Dr. Huw Jones and Richard Moulson. Dr. Huw Jones received 4,410,727 options, and Richard Moulson received 1,460,855 options. These options will vest on the third anniversary of the grant, are exercisable for up to 10 years, and result in 21,361,574 options in issue, representing 7.8% of the Company's issued share capital.
| Date | 14 Dec 2022 |
| Time | 17:08:04 |
| Category | Director/PDMR dealings |
| ID | 7510J |
("Evgen" or the "Company")
Grant of Options
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane-based medicines announces that, on 14 December 2022, certain employees and directors of the Company, including the following Persons Discharging Managerial Responsibility ("PDMR"), were granted nil cost options (the "Options") over a total of 11,122,199 ordinary shares of 0.25 pence each in the Company ("Ordinary Shares"), exercisable, subject to the Options vesting, for a period of up to 10 years from the date of grant and governed by the rules of the Evgen Pharma plc Long Term Incentive Plan ("LTIP").
|
PDMR |
Position |
Current Ordinary Shares held |
Current Options held |
New options granted |
% of issued share capital including this award |
|
Dr Huw Jones |
CEO |
62,500 |
4,648,890 |
4,410,727 |
3.3% |
|
Richard Moulson |
CFO |
45,454 |
889,728 |
1,460,855
|
0.9% |
The Options will vest on the third anniversary of grant based on performance against challenging
strategic corporate objectives over three years (40%), share price growth (30%) and on an elapsed time basis at 3 years (30%).
Following this award there are 21,361,574 options in issue, representing 7.8% of the Company's issued share capital.
Enquiries:
|
Evgen Pharma plc |
+44 1625 466591 |
|
FinnCap (Nominated Advisor and Broker) |
+44 20 7220 0500 |
|
Instinctif Partners Melanie Toyne-Sewell / Rozi Morris / Agnes Stephens / Adam Loudon |
+44 207 457 2020 |
The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
Huw Jones |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
CEO |
|
|
b) |
Initial notification /Amendment |
Initial Notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Evgen Pharma Plc |
|
|
b) |
Legal Entity Identifier |
213800NO3E6TSTQO8K20
|
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument
Identification code |
Options over Ordinary Shares of 0.25 pence each GB00BSVYN304
|
|
|
b) |
Nature of the transaction |
Grant of options |
|
|
c) |
Currency |
GBP |
|
|
d) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
nil |
4410727 |
||
|
|
|||
|
e) |
Aggregated information - Aggregated volume - Price - Aggregated total |
As above
|
|
|
f) |
Date of the transaction |
14 December 2022 |
|
|
g) |
Place of the transaction |
London Stock Exchange, AIM |
|
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
Richard Moulson |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
CFO |
|
|
b) |
Initial notification /Amendment |
Initial Notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Evgen Pharma Plc |
|
|
b) |
Legal Entity Identifier |
213800NO3E6TSTQO8K20
|
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument
Identification code |
Options over Ordinary Shares of 0.25 pence each GB00BSVYN304
|
|
|
b) |
Nature of the transaction |
Grant of options |
|
|
c) |
Currency |
GBP |
|
|
d) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
nil |
1460855 |
||
|
|
|||
|
e) |
Aggregated information - Aggregated volume - Price - Aggregated total |
As above
|
|
|
f) |
Date of the transaction |
14 December 2022 |
|
|
g) |
Place of the transaction |
London Stock Exchange, AIM |
|